Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, November 12, 2009 ) New York, NY - MabCure N.V., a subsidiary of MabCure Inc. (OTC BB: MBCI), a biotech company that has developed a series of highly specific monoclonal antibodies (Mabs) to combat various types of cancers, has signed a research agreement with AZ Sint Lucas Hospital, Brugge, Belgium. AZ Sint Lucas Hospital will conduct preclinical research intended to broaden the utility of MabCureÂ’s monoclonal antibodies for those circumstances where there is a need to diagnose cancer in tissue specimen. At present, the CompanyÂ’s Mabs for the diagnosis of ovarian cancer, prostate cancer and colorectal cancer, for example, are aimed at diagnosing early stage disease in physiological samples such as urine and serum.
Dr. Amnon Gonenne, CEO of MabCure Inc commented, “If this preclinical research works, it would open a door for us to diagnose everything that goes through surgery. This would include, for example, all of the at-risk melanoma patient population that routinely has moles removed prophylactically. The resection is arbitrary and there is currently no method to determine if the removed moles harbor early stage melanoma or not. This is critically important since melanoma is a highly lethal disease. MabCure’s Mabs may provide a definitive diagnosis of early stage melanoma in these tissue specimens thereby allowing effective treatment of the patient. An analogous situation exists in colonoscopy where it is difficult to provide definitive diagnosis of early colon cancer in the resected polyps. This approach could be extended to other organs.”
Dr. Gonnene continued, “Currently, we address multibillion-dollar opportunities with the specimens we know our Mabs are effective against. This new opportunity would allow us to cast an even wider net and we are very excited about the possibility of helping these patients.”
Studies have already begun at AZ Sint Lucas Hospital, and all scientific results will remain a property of MabCure.
About AZ Sint Lucas Hospital
The Saint Lucas General Hospital in Bruges is an independent hospital with emphasis on advanced patient care, active clinical research and participation in multi-center clinical trials.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the CompanyÂ’s website www.mabcure.com.
Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated seven thousand five hundred dollars for this advertising effort. Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately. Anyone not wishing to receive future Keros Capital Investor Reports should email us at opt-out@keroscapital.com
MabCure Inc.
Jim Mav
908-464-1747
jimmav@keroscapital.com
Source: EmailWire.com
|
|
|
|